Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: A randomised, non-inferiority, open trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Seung Ha | - |
dc.contributor.author | Kim, Dong Joon | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Lee, Heon Ju | - |
dc.contributor.author | Sohn, Joo Hyun | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Baik, Soon Koo | - |
dc.contributor.author | Lee, June Sung | - |
dc.contributor.author | Suk, Ki Tae | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Kim, Tae Yeob | - |
dc.contributor.author | Jang, Jae Young | - |
dc.date.accessioned | 2021-09-05T04:44:17Z | - |
dc.date.available | 2021-09-05T04:44:17Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97293 | - |
dc.description.abstract | Background & Aims: Both corticosteroid and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis. However, few studies have directly compared the efficacy of pentoxifylline and corticosteroid in patients with this condition. Methods: In this multicentre, open-labelled, randomised noninferiority trial, we assigned 121 patients with severe alcoholic hepatitis (Maddrey's discriminant function >= 32) to receive either pentoxifylline (400 mg, 3 times daily, in 62 subjects) or prednisolone (40 mg daily, in 59 subjects). The primary end point was non-inferiority in survival at the 1 month time point for the pentoxifylline treatment compared with prednisolone. Results: The 1-month survival rate of patients receiving pentoxifylline was 75.8% (15 deaths) compared with 88.1% (7 deaths) in those, taking prednisolone, for a treatment difference of 12.3% (95% confidence interval, 4.2% to 28.7%; p = 0.08). The 95% confidence interval for the observed difference exceeded the predefined margin of non-inferiority (Delta 15%) and included zero. The 6-month survival rate was not significantly different between the pentoxifylline and prednisolone groups (64.5% vs. 72.9%; p = 0.23). At 7 days, the response to therapy assessed by the Lille model was significantly lower in the prednisolone group (n = 58) than in the pentoxifylline group (n = 59): 0.35 vs. 0.50 (p = 0.012). Hepatitis complications, including hepatorenal syndrome and side effects, such as infection and gastrointestinal bleeding, were similar in the two groups. Conclusions: The findings demonstrate that the efficacy of the pentoxifylline is not statistically equivalent to the efficacy of prednisolone, supporting the use of prednisolone as a preferred treatment option in patients with severe alcoholic hepatitis. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | SHORT-TERM SURVIVAL | - |
dc.subject | LIVER-DISEASE | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | PREDNISOLONE | - |
dc.subject | THERAPY | - |
dc.subject | GLUCOCORTICOIDS | - |
dc.subject | METAANALYSIS | - |
dc.subject | MANAGEMENT | - |
dc.subject | STEROIDS | - |
dc.title | Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: A randomised, non-inferiority, open trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1016/j.jhep.2014.05.014 | - |
dc.identifier.scopusid | 2-s2.0-84938912078 | - |
dc.identifier.wosid | 000342252200014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATOLOGY, v.61, no.4, pp.792 - 798 | - |
dc.relation.isPartOf | JOURNAL OF HEPATOLOGY | - |
dc.citation.title | JOURNAL OF HEPATOLOGY | - |
dc.citation.volume | 61 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 792 | - |
dc.citation.endPage | 798 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SHORT-TERM SURVIVAL | - |
dc.subject.keywordPlus | LIVER-DISEASE | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PREDNISOLONE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | GLUCOCORTICOIDS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | STEROIDS | - |
dc.subject.keywordAuthor | Alcoholic hepatitis | - |
dc.subject.keywordAuthor | Corticosteroid | - |
dc.subject.keywordAuthor | Pentoxifylline | - |
dc.subject.keywordAuthor | Non-inferiority trial | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.